X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (61) 61
science & technology (61) 61
diabetes (45) 45
humans (41) 41
diabetes mellitus (33) 33
female (33) 33
male (32) 32
type 2 diabetes (32) 32
endocrinology & metabolism (30) 30
middle aged (29) 29
risk factors (29) 29
abridged index medicus (26) 26
aged (26) 26
diabetes mellitus, type 2 - drug therapy (26) 26
diabetes mellitus, type 2 - complications (21) 21
double-blind method (21) 21
cardiac & cardiovascular systems (18) 18
cardiovascular system & cardiology (18) 18
cardiovascular diseases (16) 16
analysis (15) 15
adamantane - analogs & derivatives (14) 14
clinical trials (14) 14
cardiovascular disease (13) 13
drug therapy (13) 13
kidney diseases (13) 13
complications and side effects (12) 12
hypoglycemic agents - therapeutic use (12) 12
patient outcomes (12) 12
care and treatment (11) 11
heart diseases (11) 11
myocardial infarction (11) 11
peripheral vascular disease (11) 11
treatment outcome (11) 11
dapagliflozin (10) 10
diabetics (10) 10
general & internal medicine (10) 10
heart failure (10) 10
hypoglycemic agents - adverse effects (10) 10
insulin (10) 10
medicine, general & internal (10) 10
patients (10) 10
cerebral infarction (9) 9
dosage and administration (9) 9
heart attack (9) 9
heart attacks (9) 9
hypoglycemia (9) 9
safety (9) 9
adamantane - therapeutic use (8) 8
dipeptides - adverse effects (8) 8
dipeptides - therapeutic use (8) 8
glucagon (8) 8
health aspects (8) 8
internal medicine (8) 8
liraglutide (8) 8
saxagliptin (8) 8
adamantane - adverse effects (7) 7
adult (7) 7
body weight (7) 7
cardiovascular diseases - epidemiology (7) 7
health risk assessment (7) 7
hospitalization (7) 7
hypertension (7) 7
mortality (7) 7
risk assessment (7) 7
usage (7) 7
aged, 80 and over (6) 6
arteriosclerosis (6) 6
body mass index (6) 6
cardiovascular (6) 6
dipeptidyl-peptidase iv inhibitors - adverse effects (6) 6
glomerular filtration rate (6) 6
glucose transporter (6) 6
health risks (6) 6
hypoglycemic agents - administration & dosage (6) 6
prevention (6) 6
research design (6) 6
risk (6) 6
sodium-glucose transporter 2 inhibitors - therapeutic use (6) 6
stroke (6) 6
benzhydryl compounds - therapeutic use (5) 5
blood pressure (5) 5
cardiac patients (5) 5
creatinine (5) 5
death (5) 5
diabetes mellitus, type 2 - epidemiology (5) 5
diabetic nephropathies - drug therapy (5) 5
dipeptidyl-peptidase iv inhibitors - therapeutic use (5) 5
follow-up studies (5) 5
glucagon-like peptide 1 (5) 5
glucosides - therapeutic use (5) 5
glycated hemoglobin a - analysis (5) 5
hospitalization - statistics & numerical data (5) 5
hypoglycemia - chemically induced (5) 5
hypoglycemic agents (5) 5
ischemia (5) 5
metformin (5) 5
myocardial infarction - epidemiology (5) 5
peptides (5) 5
pharmaceutical industry (5) 5
placebos (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2019, Volume 381, Issue 9, pp. 841 - 851
Journal Article
Journal Article
Diabetes care, ISSN 0149-5992, 08/2016, Volume 39, Issue Supplement 2, pp. S146 - S153
Given the increased prevalence of type 2 diabetes worldwide, most patients are treated by their primary health care team (PHCT). PHCTs need guidance in... 
Hypoglycemic Agents - therapeutic use | Practice Patterns, Physicians' - standards | Risk Reduction Behavior | United States | Humans | Diabetes Mellitus, Type 2 - therapy | Female | Israel | Hypoglycemia - drug therapy | Societies, Medical - standards | Consensus | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10166, pp. 31 - 39
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 10/2014, Volume 130, Issue 18, pp. 1579 - 1588
Journal Article
Diabetes care, ISSN 0149-5992, 06/2015, Volume 38, Issue 6, pp. 1145 - 1153
Journal Article
Diabetes care, ISSN 0149-5992, 03/2018, Volume 41, Issue 3, pp. 577 - 585
OBJECTIVE Improved risk assessment for patients with type 2 diabetes and elevated cardiovascular (CV) risk is needed. The Thrombolysis in Myocardial Infarction... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Life Style | Myocardial Infarction - epidemiology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Endpoint Determination | Adamantane - therapeutic use | Female | Registries | Stroke - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - analogs & derivatives | Body Mass Index | Stroke - prevention & control | Dipeptides - therapeutic use | Double-Blind Method | Risk Assessment | Risk Factors | Coronary Artery Disease - prevention & control | Calibration | Diet | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Type 2 diabetes | Complications and side effects | Analysis | Health risk assessment | Cardiovascular diseases | Risk factors | Heart attack | Myocardial infarction | Cerebral infarction | Stroke | Risk groups | Diabetes mellitus | Coronary artery | Health risks | Patients | Thrombosis | Coronary artery disease | Thrombolysis | Subgroups | Goodness of fit | Vascular diseases | Ischemia | Risk assessment | Atherosclerosis | Infarction | Research design | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | 0402 | Cardiovascular and Metabolic Risk
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 05/2019, Volume 139, Issue 22, pp. 2528 - 2536
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 8 - 8
A clear risk gradient was present in the full trial population, with 2-year event rates for the composite end point of 3.0%, 5.6%, and 12.0% in the lowest,... 
Cardiovascular | Internal Medicine | Prevention | Medical colleges | Diabetics | Heart diseases | Disease prevention | Physicians | Diabetes
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 1653 - 1653
Conclusions: In patients with diabetes and elevated CV risk, there is a J-shaped relationship between MACE and baseline blood pressure as well as increased... 
Cardiovascular | Internal Medicine | Diabetics | Blood pressure | Cardiovascular diseases | Patient outcomes | Risk factors | Prescription drugs | Cardiovascular disease | Stratigraphy | Diabetes | Beta blockers
Journal Article
The Lancet (British edition), ISSN 0140-6736, 08/2018, Volume 392, Issue 10148, pp. 637 - 649
Journal Article